One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Understanding Device Development for Gastrointestinal Clinical Care
Beck, Kendall R. MD1; Shah, Eric D. MD, MBA2; Hernandez-Barco, Yasmin G. MD3; ACG FDA-Related Matters Committee
doi : 10.14309/ajg.0000000000001126
June 2021 - Volume 116 - Issue 6 - p 1107-1109
Effective Mentorship as a Means to Recruit, Retain, and Promote Underrepresented Minorities in Academic Gastroenterology and Hepatology
Louissaint, Jeremy MD1; May, Folasade P. MD PhD2,3,4; Williams, Sydni BA5; Tapper, Elliot B. MD1,6
doi : 10.14309/ajg.0000000000001125
June 2021 - Volume 116 - Issue 6 - p 1110-1113
Inferior Mesenteric Arteriovenous Malformation Masquerading as Ulcerative Colitis
Zaver, Himesh B. MD1; Ghoz, Hassan MD2; Azar, Antoine MD3; Alexander, Lauren F. MD3; Toskich, Beau MD3; Edgar, Mark A. MD4; Krishna, Murli MD4; Colibaseanu, Dorin T. MD5; Brahmbhatt, Bhaumik MD2; Farraye, Francis A. MD, MSc2
doi : 10.14309/ajg.0000000000000917
June 2021 - Volume 116 - Issue 6 - p 1114
A Rare Case of Clear Cell Sarcoma-Like Tumor of the Stomach and Duodenum
Tocia, Cristina MD, PhD1,2; Dumitru, Andrei MD1,2; Micu, Luminita Gentiana MD, PhD3; Mazilu, Laura MD, PhD1,4; Dumitru, Eugen MD, PhD1,2
doi : 10.14309/ajg.0000000000000915
June 2021 - Volume 116 - Issue 6 - p 1115
Ipsilateral Abdominal Bulge Caused by Postherpetic Pseudohernia
Nakagawa, Hiroaki MD1; Miyata, Yasushi MD, PhD2
doi : 10.14309/ajg.0000000000000916
June 2021 - Volume 116 - Issue 6 - p 1116
Metastatic Lung Adenocarcinoma to Multiple Bile Ducts Mimicking Sclerosing Cholangitis
Matsumoto, Kengo MD, PhD1; Nishida, Tsutomu MD, PhD1; Yamamoto, Masashi MD, PhD1
doi : 10.14309/ajg.0000000000000944
June 2021 - Volume 116 - Issue 6 - p 1117
Positron Emission Tomography/Computed Tomography-Based Diagnosis of Endotipsitis
Casas Deza, D. MD1; Sierra Gabarda, O. MD1; De los Mozos Ruano, A. MD2; Lamuela Calvo, L.J. MD1; Garc?a L?pez, S. PhD1; Fuentes Olmo, J. PhD1
doi : 10.14309/ajg.0000000000000950
June 2021 - Volume 116 - Issue 6 - p 1118
Endoscopic Retrograde Appendicitis Therapy for Treating Periappendiceal Abscess: First Human Case Report
Song, Mingyang MD1,2; Ullah, Saif MD1; Liu, Bingrong MD, PhD1,3
doi : 10.14309/ajg.0000000000001116
June 2021 - Volume 116 - Issue 6 - p 1119
Continuing Medical Education Questions: June 2021
Howard, Dominique E. MD, FACG
doi : 10.14309/ajg.0000000000001316
June 2021 - Volume 116 - Issue 6 - p 1122
Article Title: ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections
Continuing Medical Education Questions: June 2021
Sadowski, Brett W. MD
doi : 10.14309/ajg.0000000000001315
June 2021 - Volume 116 - Issue 6 - p 1123
Article Title: Exploratory comparative effectiveness trial of green kiwifruit, psyllium, or prunes in US patients with chronic constipation
ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections
Kelly, Colleen R. MD, AGAF, FACG1; Fischer, Monika MD, MSc, AGAF, FACG2; Allegretti, Jessica R. MD, MPH, FACG3; LaPlante, Kerry PharmD, FCCP, FIDSA4; Stewart, David B. MD, FACS, FASCRS5; Limketkai, Berkeley N. MD, PhD, FACG (GRADE Methodologist)6; Stollman, Neil H. MD, FACG7
doi : 10.14309/ajg.0000000000001278
June 2021 - Volume 116 - Issue 6 - p 1124-1147
Clostridioides difficile infection occurs when the bacterium produces toxin that causes diarrhea and inflammation of the colon. These guidelines indicate the preferred approach to the management of adults with C. difficile infection and represent the official practice recommendations of the American College of Gastroenterology. The scientific evidence for these guidelines was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation process. In instances where the evidence was not appropriate for Grading of Recommendations Assessment, Development, and Evaluation but there was consensus of significant clinical merit, key concept statements were developed using expert consensus. These guidelines are meant to be broadly applicable and should be viewed as the preferred, but not the only, approach to clinical scenarios.
Celiac Disease: Fallacies and Facts
Silvester, Jocelyn A. MD, PhD1,2; Therrien, Amelie MD, MS1; Kelly, Ciaran P. MD1
doi : 10.14309/ajg.0000000000001218
June 2021 - Volume 116 - Issue 6 - p 1148-1155
Our understanding of the pathophysiology of celiac disease has progressed greatly over the past 25 years; however, some fallacies about the clinical characteristics and management persist. Worldwide epidemiologic data are now available showing that celiac disease is ubiquitous. An elevated body mass index is common at the time of the diagnosis. The gluten-free diet (GFD) is an imperfect treatment for celiac disease; not all individuals show a response. This diet is widely used by people without celiac disease, and symptomatic improvement on a GFD is not sufficient for diagnosis. Finally, the GFD is burdensome, difficult to achieve, and thus has an incomplete efficacy, opening exciting opportunities for novel, nondietary treatments.
Efficacy and Safety of Over-the-Counter Therapies for Chronic Constipation: An Updated Systematic Review
Rao, Satish S.C. MD, PhD1; Brenner, Darren M. MD2
doi : 10.14309/ajg.0000000000001222
June 2021 - Volume 116 - Issue 6 - p 1156-1181
Constipation is commonly treated with over-the-counter (OTC) products whose efficacy and safety remain unclear. We performed a systematic review of OTC therapies for chronic constipation and provide evidence-based recommendations.
Disparate Health Care in Barrett's Esophagus: The First Step Is Awareness
Katzka, David A. MD1
doi : 10.14309/ajg.0000000000001262
June 2021 - Volume 116 - Issue 6 - p 1182-1183
Disparities in medical treatment related to differences in race, gender, and creed are present in all fields of practice. This a complex issue requires multiple perspectives to gain advancements in patient care. This editorial examines the recently published article uses the GI Quality Improving Consortium to investigate disparities in adherence to quality indicators in Barrett's esophagus.
The Three Villages of Hepatic Encephalopathy
Bajaj, Jasmohan S. MD, FACG1
doi : 10.14309/ajg.0000000000001212
June 2021 - Volume 116 - Issue 6 - p 1184-1186
Hepatic encephalopathy (HE) affects numerous stakeholders from a clinical, psychosocial, and financial perspective. The multilayered impact of HE is threefold and affects different groups or, for the purpose of this commentary, villages. The first village mediates HE development, including genetics, microbiome, and disease severity. The second village consists of those affected by HE-related consequences, including the patient, caregivers, society, and medical system. The third village required to manage HE includes a multidisciplinary team of inpatient and outpatient providers, mental health experts, physical therapists, and dietary specialists. Understanding and integration of these three villages can encourage individualized care for patients and families affected by hepatic encephalopathy.
Progress in Corticosteroid Use in the Era of Biologics With Room for Improvement
Abdalla, Maisa I. MD, MPH1; Levesque, Barrett G. MD, MS2
doi : 10.14309/ajg.0000000000001261
June 2021 - Volume 116 - Issue 6 - p 1187-1188
With the early success of their trials for the treatment of ulcerative colitis, corticosteroids gained popularity as a treatment for inflammatory bowel disease (IBD). However, when used chronically, corticosteroids are not effective in maintaining remission and associated with toxic effects. Steroid-free remission has become a major treatment goal. Prolonged corticosteroid use is currently a sign of suboptimal quality of care. Trends over the past 2 decades, spanning the emergence of biologic therapies for IBD, are explored here in the University of Manitoba IBD Epidemiologic Database.
The Perils and Pitfalls of Esophageal Dysmotility in Idiopathic Pulmonary Fibrosis
Cheah, Ramsah PhD1,2; Chirnaksorn, Supphamat MD1,3; Abdelrahim, Ahmed H. MD4; Horgan, Laura MBChB5; Capstick, Toby BSc, DPharm5; Casey, John MSc6; Peckham, Daniel MBBS, DM5; Boland, Alison MBChB5; Sutherland, Timothy J. T. MBChB, PhD5; Beirne, Paul MA, MSc, PhD5; Lee, Augustine S. MD4; DeVault, Kenneth R. MD7; Houghton, Lesley A. PhD, AGAF, FACG1,2,7
doi : 10.14309/ajg.0000000000001202
June 2021 - Volume 116 - Issue 6 - p 1189-1200
Gastroesophageal reflux plays a significant role in idiopathic pulmonary fibrosis (IPF). Given the morbidity and mortality associated with IPF, understanding the mechanisms responsible for reflux is essential if patients are to receive optimal treatment and management, especially given the lack of clear benefit of antireflux therapies. Our aim was to understand the inter-relationships between esophageal motility, lung mechanics and reflux (particularly proximal reflux—a prerequisite of aspiration), and pulmonary function in patients with IPF.
Racial Disparities in Adherence to Quality Indicators in Barrett's Esophagus: An Analysis Using the GIQuIC National Benchmarking Registry
Jones, Blake MD1; Williams, J. Lucas MPH2; Komanduri, Srinadh MD3; Muthusamy, V. Raman MD4; Shaheen, Nicholas J. MD, MPH5; Wani, Sachin MD1
doi : 10.14309/ajg.0000000000001230
June 2021 - Volume 116 - Issue 6 - p 1201-1210
Racial disparities in outcomes in esophageal adenocarcinoma are well established. Using a nationwide registry, we aimed to compare clinical and endoscopic characteristics of blacks and whites with Barrett's esophagus (BE) and adherence to defined quality indicators.
Use of Proton Pump Inhibitors vs Histamine 2 Receptor Antagonists for the Risk of Gastric Cancer: Population-Based Cohort Study
Shin, Ga-Yeong MD1; Park, Jae Myung MD1; Hong, Jinhyuk MS2; Cho, Yu Kyung MD1; Yim, Hyeon Woo MD2; Choi, Myung-Gyu MD1
doi : 10.14309/ajg.0000000000001167
June 2021 - Volume 116 - Issue 6 - p 1211-1219
Proton pump inhibitors (PPIs) are commonly prescribed medications. Long-term use of PPIs has been suspected to have a provocative effect on gastric cancer. This study was to determine the association between PPI vs histamine 2 receptor antagonist (H2RA) use and the risk of gastric cancer in a region where the risk of this malignancy is high.
Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg)
Nyssen, Olga P. BSc1; Perez-Aisa, Angeles MD2; Tepes, Bojan MD3; Castro-Fernandez, Manuel MD4; Kupcinskas, Juozas MD5; Jonaitis, Laimas MD5; Bujanda, Luis MD6; Lucendo, Alfredo MD7; Jurecic, Natasa Brglez MD8; Perez-Lasala, Jorge MD9; Shvets, Oleg MD10; Fadeenko, Galina MD11; Huguet, Jose M. MD12; Kikec, Zdenki MD13; Bordin, Dmitry MD14,15,16; Voynovan, Irina MD14; Leja, Marcis MD17; Machado, Jose Carlos MD18; Areia, Miguel MD19; Fernandez-Salazar, Luis MD20; Rodrigo, Luis MD21; Alekseenko, Sergey MD22; Barrio, Jesus MD23; Ortu?o, Juan MD24; Perona, Monica MD25; Vologzhanina, Liudmila MD26; Romero, Pilar Mata MD27; Zaytsev, Oleg MD28; Rokkas, Theodore MD29; Georgopoulos, Sotirios MD30; Pellicano, Rinaldo MD31; Buzas, Gyorgy M. MD32; Modolell, Ines MD33; Gomez Rodriguez, Blas Jose MD34; Simsek, Ilkay MD35; Simsek, Cem MD36; Lafuente, Marina Roldan MD37; Ilchishina, Tatiana MD38; Camarero, Judith Gomez MD39; Dominguez-Cajal, Manuel MD40; Ntouli, Vassiliki MD41; Dekhnich, Natalia Nikolaevna MD42; Phull, Perminder MD43; Nu?ez, Oscar MD44; Lerang, Frode MD45; Venerito, Marino MD46; Heluwaert, Frederic MD47; Tonkic, Ante MD48; Caldas, Maria MD1; Puig, Ignasi MD49; Megraud, Francis MD50; O'Morain, Colm MD51; Gisbert, Javier P. MD1, On behalf of the Hp-EuReg Investigators*
doi : 10.14309/ajg.0000000000001246
June 2021 - Volume 116 - Issue 6 - p 1220-1229
The safety of Helicobacter pylori eradication treatments and to what extent adverse events (AEs) influence therapeutic compliance in clinical practice are hardly known. Our aim was to assess the frequency, type, intensity, and duration of AEs, and their impact on compliance, for the most frequently used treatments in the “European Registry on Helicobacter pylori management.”
Influence of Sedation on the Detection Rate of Early Cancer and Precancerous Lesions During Diagnostic Upper Gastrointestinal Endoscopies: A Multicenter Retrospective Study
Zhou, Jiawei MD1,2,3; Li, Zhen MD1,2,3; Ji, Rui MD1; Wang, Peizhu MS1,2,3; Zhang, Aijun BS4; Wu, Kangkang MS4; Liu, Chengxia PhD5; Niu, Qiong BS5; Chu, Yanliu MD6; Su, Xiufeng MD6; Zuo, Xiuli MD1,2,3; Li, Yanqing MD1,2,3
doi : 10.14309/ajg.0000000000001201
June 2021 - Volume 116 - Issue 6 - p 1230-1237
The influence of sedation on the endoscopic detection rate of upper gastrointestinal (UGI) early cancer (EC) and precancerous lesions, including high-grade intraepithelial neoplasia (HGIN) and low-grade intraepithelial neoplasia, has not been assessed. The aim of this research is to assess whether the use of sedation can help improve the detection rate of UGI EC and precancerous lesions. The second objective is to evaluate its potential influencing factors.
Development and Validation of a Clinical-Genetic Risk Score to Predict Hepatic Encephalopathy in Patients With Liver Cirrhosis
Gil-G?mez, Antonio PhD1,2; Ampuero, Javier MD, PhD1,2,3; Rojas, ?ngela PhD1,2; Gallego-Dur?n, Roc?o PhD1,2; Mu?oz-Hern?ndez, Roc?o PhD1,2; Rico, Mar?a C. BSc1,2; Mill?n, Raquel BSc1,2; Garc?a-Lozano, Ra?l MD, PhD4; Francés, Rubén MD, PhD2,5,6; Soriano, Germ?n MD, PhD2,7; Romero-G?mez, Manuel MD, PhD1,2,3
doi : 10.14309/ajg.0000000000001164
June 2021 - Volume 116 - Issue 6 - p 1238-1247
We aimed to define the impact of the genetic background on overt hepatic encephalopathy (HE) in patients with liver cirrhosis by developing a combined clinical-genetic risk score.
Factors Enhancing Treatment of Hepatitis C Virus–Infected Italian People Who Use Drugs: The CLEO-GRECAS Experience
Rinaldi, Luca MD, PhD1; Messina, Vincenzo MD2; Di Marco, Vito MD3; Iovinella, Vincenzo MD4; Claar, Ernesto MD5; Cariti, Giuseppe MD6; Sacco, Rodolfo MD7; De Luca, Massimo MD8; Scifo, Gaetano MD9; Gatti, Pietro MD10; Barbarini, Giorgio MD11; Pace Palitti, Valeria MD12; Quartini, Mariano MD13; Tundo, Paolo MD14; D'Offizi, Gianpiero MD15; Parruti, Giustino MD16; di Rosolini, Maria Antonietta MD17; Garrucciu, Giovanni MD18; Cosco, Lucio MD19; Benanti, Francesco MD20; Gimignani, Giancarlo MD21; Vespasiani Gentilucci, Umberto MD22; Di Lorenzo, Francesco MD23; D'Ant?, Maria MD24; Nevola, Riccardo MD1; Lupia, Tommaso MD6; Rosato, Valerio MD5; Morbiducci, Valeria MD13; Luzzitelli, Ilaria MD15; Sozio, Federica MD16; Di Stefano, Marco MD9; Ciraci, Emanuela MD10; Bulla, Fabio MD19; Guarisco, Riccardo MD21; Cangiano, Cecilia MD1; Imparato, Michele MD25; Maggi, Paolo MD2; Ascione, Antonio MD25; Crax?, Antonio MD3; Izzi, Antonio MD26
doi : 10.14309/ajg.0000000000001147
June 2021 - Volume 116 - Issue 6 - p 1248-1255
We assessed the performance of direct-acting antivirals (DAAs) in hepatitis C virus (HCV)-infected people who use drugs (PWUDs) in terms of sustained virological response (SVR) and adherence rates in comparison to a location-matched cohort of non-PWUD HCV patients.
Childhood and Adulthood Passive Smoking and Nonalcoholic Fatty Liver in Midlife: A 31-year Cohort Study
Wu, Feitong PhD1; Pahkala, Katja PhD2,3,4; Juonala, Markus MD, PhD5,6; Jaakkola, Johanna PhD2,4; Rovio, Suvi P. PhD2,4; Lehtim?ki, Terho MD, PhD7; Sabin, Matthew A. MD, PhD8; Jula, Antti MD, PhD9; Hutri-K?h?nen, Nina MD, PhD10; Laitinen, Tomi MD, PhD11; Viikari, Jorma S.A. MD, PhD5,6; Magnussen, Costan G. PhD1,2,4; Raitakari, Olli T. MD, PhD2,4,12
doi : 10.14309/ajg.0000000000001141
June 2021 - Volume 116 - Issue 6 - p 1256-1263
Identifying early life risk factors remains key to the prevention of nonalcoholic fatty liver (hereinafter “fatty liver”) in adulthood. However, the longitudinal association of childhood passive smoking with adult fatty liver is not studied. We examined the association of childhood and adulthood passive smoking with fatty liver in midlife.
Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir
Nguyen, Mindie H. MD, MAS1; Atsukawa, Masanori MD, PhD2; Ishikawa, Toru MD, PhD3; Yasuda, Satoshi MD, PhD4; Yokohama, Keisuke MD, PhD5; Trinh, Huy N. MD6; Arai, Taeang MD, PhD2; Fukunishi, Shinya MD, PhD7; Ogawa, Eiichi MD, PhD8; Hsu, Yao-Chun MD, PhD9; Maeda, Mayumi MD1; Dang, Hansen BS1; Tseng, Cheng-Hao MD9; Takahashi, Hirokazu MD, PhD10,11; Jun, Dae Won MD, PhD12; Watanabe, Tsunamasa MD, PhD13; Chuma, Makoto MD, PhD14; Nozaki, Akito MD, PhD14; Kawada, Norifumi MD, PhD15; Cheung, Ramsey MD1,16; Enomoto, Masaru MD, PhD15; Takaguchi, Koichi MD, PhD17; Toyoda, Hidenori MD, PhD4
doi : 10.14309/ajg.0000000000001157
June 2021 - Volume 116 - Issue 6 - p 1264-1273
Entecavir (ETV) and tenofovir alafenamide (TAF) are both first-line hepatitis B virus (HBV) therapies, but ETV-to-TAF switch outcome data are limited. We aimed to assess outcomes up to 96 weeks after ETV-to-TAF switch.
Hepatitis Flare During Immunotherapy in Patients With Current or Past Hepatitis B Virus Infection
Wong, Grace Lai-Hung MD1,2,3; Wong, Vincent Wai-Sun MD1,2,3; Hui, Vicki Wing-Ki BSc1,2,3; Yip, Terry Cheuk-Fung PhD1,2,3; Tse, Yee-Kit MPhil1,2,3; Liang, Lilian Yan MD1,2,3; Lui, Rashid Nok-Shun MBChB1,2,3; Mok, Tony Shu-Kam MD4; Chan, Henry Lik-Yuen MD1,2,3; Chan, Stephen Lam MD4
doi : 10.14309/ajg.0000000000001142
June 2021 - Volume 116 - Issue 6 - p 1274-1283
Immunotherapy has dramatically improved the survival of patients with advanced or metastatic malignancies. Recent studies suggest that immunotherapy may increase the risk of hepatitis, whereas it may also induce functional cure of chronic hepatitis B virus (HBV) infection. We evaluated the incidence of hepatitis flare, HBV reactivation, hepatitis B surface antigen (HBsAg) seroclearance or seroreversion in patients with current or past HBV infection who had received immunotherapy.
Trends in Corticosteroid Use During the Era of Biologic Therapy: A Population-Based Analysis
Targownik, Laura E. MD, MSHS, FRCPC1; Bernstein, Charles N. MD2; Benchimol, Eric I. MD, PhD3,4,5; Kaplan, Gilaad G. MD, MPH6; Singh, Harminder MD, MPH2,7; Tennakoon, Aruni MSc2; Nugent, Zoann PhD2; Coward, Stephanie B. PhD6; Kuenzig, M. Ellen PhD8,9; Murthy, Sanjay K. MD, MSc10
doi : 10.14309/ajg.0000000000001220
June 2021 - Volume 116 - Issue 6 - p 1284-1293
Corticosteroids are effective for inducing clinical remission in inflammatory bowel disease (IBD), but not for maintaining remission. Reducing corticosteroid use and dependence is an important treatment goal since their use is associated with adverse events. The extent to which the improvements in IBD therapy have led to less corticosteroid use in the modern era remains unclear.
Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2)
Chey, William D. MD, AGAF, FACG, FACP, RFF1; Lembo, Anthony J. MD2; Yang, Yang PhD3; Rosenbaum, David P. PhD3
doi : 10.14309/ajg.0000000000001056
June 2021 - Volume 116 - Issue 6 - p 1294-1303
Tenapanor is a first-in-class, minimally absorbed, small-molecule inhibitor of the gastrointestinal sodium/hydrogen exchanger isoform 3. This phase 3 trial assessed the long-term efficacy and safety of tenapanor 50 mg b.i.d. for the treatment of patients with irritable bowel syndrome with constipation (IBS-C).
Exploratory Comparative Effectiveness Trial of Green Kiwifruit, Psyllium, or Prunes in US Patients With Chronic Constipation
Chey, Samuel W. MPH1; Chey, William D. MD1; Jackson, Kenya BS1,2; Eswaran, Shanti MD1
doi : 10.14309/ajg.0000000000001149
June 2021 - Volume 116 - Issue 6 - p 1304-1312
Psyllium and prunes are proven treatments for chronic constipation (CC). Asian studies suggest that kiwifruit may also benefit CC symptoms. We report a partially randomized, comparative effectiveness trial evaluating kiwifruit, psyllium, and prunes in US patients with CC.
Combined Use of Aspirin and Selective Serotonin Reuptake Inhibitors Is Associated With Lower Risk of Colorectal Cancer: A Nested Case-Control Study
Zhang, Naiqi MPhil1; Sundquist, Jan MD, PhD1,2,3; Sundquist, Kristina MD, PhD1,2,3; Zhang, Zhi-Gang PhD4; Ji, Jianguang MD, PhD1
doi : 10.14309/ajg.0000000000001192
June 2021 - Volume 116 - Issue 6 - p 1313-1321
Chemoprevention against colorectal cancer (CRC) is greatly needed. As the development of CRC involves multiple dysfunctional pathways, it is thus reasonable to combine some agents that address several pathways to achieve better chemoprotection. We aimed to explore whether the use of aspirin and selective serotonin reuptake inhibitors (SSRIs)—either as monotherapy or combined—can have a clinical benefit against CRC.
Do Children With Functional Abdominal Pain Benefit More From a Pain-Specific Cognitive-Behavioral Intervention Than From an Unspecific Attention Control Intervention? Results of a Randomized Controlled Trial
Warschburger, Petra Prof Dr1; Calvano, Claudia PhD1,2; Becker, Sebastian MD3; Ebinger, Friedrich Prof Dr4; Hudert, Christian MD5; Iven, Enno MD6; Posovszky, Carsten PD Dr7; Winter, Sibylle-Maria Prof Dr2; Daubmann, Anne Dipl-Stat8; Ozga, Ann-Kathrin PhD8; Wegscheider, Karl Prof Dr8
doi : 10.14309/ajg.0000000000001191
June 2021 - Volume 116 - Issue 6 - p 1322-1335
We aimed to compare the efficacy of cognitive-behavioral therapy (CBT) among children with functional abdominal pain with an attention control (AC), hypothesizing the superiority of CBT group intervention regarding pain intensity (primary outcome), pain duration and frequency (further primary outcomes), functional disability, and quality of life and coping strategies (key secondary outcomes).
Variability in Practices of Compounding Budesonide for Eosinophilic Esophagitis
Joshi, Sagar MD1; Rubenstein, Joel H. MD, MSc2,3; Dellon, Evan S. MD, MPH4; Worthing, Nathan PharmD5; Stefanadis, Zoe RPh6; Chang, Joy W. MD, MS3
doi : 10.14309/ajg.0000000000001170
June 2021 - Volume 116 - Issue 6 - p 1336-1338
Little is known about the use of compounded steroids for eosinophilic esophagitis (EoE).
Novel Negative Pressure Protective Box in Upper Digestive Endoscopy: A Prospective Case Series
Benmassaoud, Amine MD1; Bessissow, Talat MD, MSc1; Wong, Philip MD, MSc1; Fallone, Carlo A. MD1; Barkun, Alan MD, MSc1; Afif, Waqqas MD, MSc1; Forbes, Nauzer MD, MSc2; Martel, Myriam MSc1; Geraci, Olivia BA1; Chen, Yen-I MD, MSc1
doi : 10.14309/ajg.0000000000001221
June 2021 - Volume 116 - Issue 6 - p 1339-1341
In the context of the Severe Acute Respiratory Syndrome Coronavirus 2 pandemic, we have developed a novel negative pressure aerosol protector for upper endoscopy (TRACEY). TRACEY is the first endoscopic enclosure to have passed stringent testing for aerosol protection. The following describes its clinical use in a single-center prospective case series. Overall, 15 patients were included. All endoscopic procedures were successful without premature removal of TRACEY. In addition, its use did not lead to significant patient discomfort, technical hinderance, or adverse events. TRACEY seems to offer a safe and easy to use aerosol protection for upper endoscopy and a potential Severe Acute Respiratory Syndrome Coronavirus 2 mitigation strategy in endoscopy.
Decompensation in Direct-Acting Antiviral Cured Hepatitis C Virus Compensated Patients With Clinically Significant Portal Hypertension: Too Rare to Warrant Universal ?-Blocker Therapy
Tosetti, Giulia MD1; Degasperi, Elisabetta MD, PhD1; Farina, Elisa MD1; D'Ambrosio, Roberta MD1; Soffredini, Roberta PhD1; Borghi, Marta1; La Mura, Vincenzo MD, PhD1,2; Primignani, Massimo MD1; Lampertico, Pietro MD, PhD1,3
doi : 10.14309/ajg.0000000000001158
June 2021 - Volume 116 - Issue 6 - p 1342-1344
Nonselective ?-blockers improve decompensation-free survival in viremic hepatitis C virus compensated cirrhotic patients with clinically significant portal hypertension, but their protective role after sustained virological response by direct-acting antiviral (DAA) is undefined. We evaluated the incidence of decompensation in DAA-cured Child-A patients without high-risk varices. During the 49-month (12–60) follow-up, only one of 148 patients decompensated (ascites), with a 4-year cumulative risk of 1%, but decompensation was associated with hepatocellular carcinoma. The risk of decompensation in DAA cured hepatitis C virus compensated Child-A cirrhotic patients with clinically significant portal hypertension but without high-risk varices is negligible; thus, questioning the need for nonselective ?-blocker treatment in this setting (see Visual abstract, Supplemental Digital Content, 1, http://links.lww.com/AJG/B861).
COVID-19 Vaccine Perceptions Among Patients With Chronic Disease in a Large Gastroenterology and Hepatology Practice
Serper, Marina MD, MS1,2; Reddy, K. Rajender MD1; Bewtra, Meenakshi MD, PhD, MPH1,3,4; Ahmad, Nuzhat MD1; Mehta, Shivan J. MD, MBA, MSHP1,2,5
doi : 10.14309/ajg.0000000000001270
June 2021 - Volume 116 - Issue 6 - p 1345-1349
To assess beliefs about safety, effectiveness, and delivery of the coronavirus disease 2019 (COVID-19) vaccine among chronic Gastroenterology and Hepatology patients at an academic health system.
Prion Gene PRNP Y162X Truncation Mutation Can Induce a Refractory Esophageal Achalasia
Matsuzono, Kosuke MD, PhD1; Kim, Younhee MD1; Honda, Hiroyuki MD, PhD2; Anan, Yuhei MD1; Tsunoda, Masato MD3; Amano, Yusuke DDS, PhD4; Fukusima, Noriyoshi MD, PhD4; Iwaki, Toru MD, PhD2; Kitamoto, Tetsuyuki MD, PhD5; Fujimoto, Shigeru MD, PhD1
doi : 10.14309/ajg.0000000000001044
June 2021 - Volume 116 - Issue 6 - p 1350-1351
“Presbyesophagus” No!
Khalaf, Mohamed MD1; Elias, Puja S. MD1; Castell, Donald O. MD1
doi : 10.14309/ajg.0000000000001128
June 2021 - Volume 116 - Issue 6 - p 1351-1352
Bile Acid Sequestrants Are Contraindicated for Patients With Hypertrigly-ceridemia: A Case Report
Malecki, Elise A. MD, PhD1,2
doi : 10.14309/ajg.0000000000001161
June 2021 - Volume 116 - Issue 6 - p 1352
Efficacy of Senna and Magnesium Oxide for the Treatment of Chronic Idiopathic Constipation
Goodoory, Vivek C. MBChB, MRCP1; Black, Christopher J. MBBS, MRCP1,2; Ford, Alexander C. MD1,2
doi : 10.14309/ajg.0000000000001041
June 2021 - Volume 116 - Issue 6 - p 1352-1353
Response to Goodoory et al.
Tomita, Toshihiko MD, PhD1; Morishita, Daisuke MD, PhD1; Miwa, Hiroto MD, PhD1
doi : 10.14309/ajg.0000000000001099
June 2021 - Volume 116 - Issue 6 - p 1353-1354
Pay Attention to Distinguish Hepatitis from Novel Coronavirus Hepatitis in the Context of COVID-19 Pandemic
Yu, Xianqiang PhD1
doi : 10.14309/ajg.0000000000001144
June 2021 - Volume 116 - Issue 6 - p 1354-1355
Problems for Gastrointestinal Patients With Diarrheal Disorders: Limited Access to Public Bathrooms Because Previously Open Public Bathrooms Have Closed Due to COVID-19 Pandemic and Inadequate Number of Bathrooms in Some Endoscopy Suites
Cappell, Mitchell S. MD, PhD1,2
doi : 10.14309/ajg.0000000000001082
June 2021 - Volume 116 - Issue 6 - p 1355-1356
Vascular Hamartoma of the Pancreas
Jha, Ashesh Kumar MS1
doi : 10.14309/ajg.0000000000001083
June 2021 - Volume 116 - Issue 6 - p 1356-1357
COVID-19 Patients With Hepatitis B Virus Infection
Lv, Xiu-He MD1,2; Yang, Jin-Lin MD1,2; Deng, Kai MD1,2,3,4
doi : 10.14309/ajg.0000000000001034
June 2021 - Volume 116 - Issue 6 - p 1357-1358
Sarcopenia and TIPS: How Best to Measure Muscle Mass
Debnath, Prasanta MD, DM1; Rathi, Pravin MD, DM, DNB1
doi : 10.14309/ajg.0000000000001091
June 2021 - Volume 116 - Issue 6 - p 1358
Response to Debnath and Rathi
Benmassaoud, Amine MD1; Tsochatzis, Emmanuel MD2,3
doi : 10.14309/ajg.0000000000001150
June 2021 - Volume 116 - Issue 6 - p 1358-1359
SARS-CoV-2 Impact on Screening Colonoscopy: Implications for Postpandemic Recovery
Aggarwal, Aakash MD1; Jain, Amit MD2; Jain, Punya BS3; Sangha, Maheep MD1; Benias, Petros C. MD1; Trindade, Arvind J. MD4; and the Northwell COVID-19 Research Consortium
doi : 10.14309/ajg.0000000000001097
June 2021 - Volume 116 - Issue 6 - p 1359-1360
Quantity of Donor Stool for Fecal Microbiota Transplantation: The More, the Better?
Ianiro, Gianluca MD, PhD1; Porcari, Serena MD1; Gasbarrini, Antonio MD1; Cammarota, Giovanni MD1
doi : 10.14309/ajg.0000000000001130
June 2021 - Volume 116 - Issue 6 - p 1360-1361
Response to Ianiro et al.
Craven, Laura J. PhD1; Parvathy, Seema Nair PhD2; Burton, Jeremy P. PhD1,3,4; Silverman, Michael S. MD1,2,3
doi : 10.14309/ajg.0000000000001160
June 2021 - Volume 116 - Issue 6 - p 1361-1362
A Targeted Approach to Managing Chronic Pouchitis: Incorporating Accurate Phenotyping of Pouchitis and Assessment for Coexisting Dyssynergic Defecation
Ardalan, Zaid S. MBChB, FRACP1; Sparrow, Miles P. MBBS, FRACP1
doi : 10.14309/ajg.0000000000001129
June 2021 - Volume 116 - Issue 6 - p 1362
Calendar of Courses, Symposiums and Conferences
doi : 10.14309/ajg.0000000000001317
June 2021 - Volume 116 - Issue 6 - p 1363
